Modulation of Docetaxel-induced Apoptosis and Cell Cycle Arrest by All- Trans Retinoic Acid in Prostate Cancer Cells

Overview

Journal Br J Cancer

Specialty Oncology

Date 2001 Jun 1

PMID 11384110

Citations 27

Authors

A Nehme

P Varadarajan

G Sellakumar

M Gerhold

H Niedner

Q Zhang

X Lin

R D Christen

Affiliations

Soon will be listed here.

Abstract

We report that all- trans retinoic acid (ATRA) enhanced the toxicity of docetaxel against DU145 and LNCaP prostate cancer cells, and that the nature of the interaction between ATRA and docetaxel was highly synergistic. Docetaxel-induced apoptotic cell death was associated with phosphorylation and hence inactivation of Bcl-2. ATRA enhanced docetaxel-induced apoptosis and combined treatment with ATRA and docetaxel resulted in down-regulation of Bcl-2. Docetaxel caused phosphorylation and hence inactivation of cdc2 kinase result ing in G2/M arrest. ATRA inhibited docetaxel-induced phosphorylation of cdc2 resulting in activation of cdc2 kinase and partial reversal of the G2/M arrest. ATRA also inhibited docetaxel-induced activation of MAPK indicating that the effects of docetaxel and ATRA on cdc2 phosphorylation are dependent on MAPK. We conclude that ATRA synergistically enhances docetaxel toxicity by down-regulating Bcl-2 expression and partially reverses the docetaxel-induced G2/M arrest by inhibiting docetaxel-induced cdc2 phosphorylation in a pathway that is dependent on MAPK.

Citing Articles

Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy.

Wei L, Zhang Q, Zhong C, He L, Zhang Y, Armaly A Mol Oncol. 2023; 17(10):1962-1980.

PMID: 37357618 PMC: 10552894. DOI: 10.1002/1878-0261.13478.

Nanoencapsulation of Docetaxel Induces Concurrent Apoptosis and Necroptosis in Human Oral Cancer Cells (SCC-9) via TNF-α/RIP1/RIP3 Pathway.

Gupta P, Singh A, Verma A, Kant S, Pandey A, Mishra A Indian J Clin Biochem. 2023; 38(3):351-360.

PMID: 37234186 PMC: 10205939. DOI: 10.1007/s12291-022-01055-7.

CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer.

Kim S, Lee K, Park J, Park M, Kim U, Kim S Toxicol Res. 2023; 39(1):61-69.

PMID: 36726834 PMC: 9839922. DOI: 10.1007/s43188-022-00146-0.

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy.

Duan X, Liu K, Jiao X, Qin B, Li B, He X Front Oncol. 2023; 12:1007146.

PMID: 36686739 PMC: 9847361. DOI: 10.3389/fonc.2022.1007146.

Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies.

Li Y, Xu C, Wang B, Xu F, Ma F, Qu Y Nat Commun. 2022; 13(1):5723.

PMID: 36175412 PMC: 9522856. DOI: 10.1038/s41467-022-33282-0.

References

Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell V . Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999; 13(11):1881-92. DOI: 10.1038/sj.leu.2401573. View

Shtil A, Mandlekar S, Yu R, Walter R, Hagen K, Tan T . Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene. 1999; 18(2):377-84. DOI: 10.1038/sj.onc.1202305. View

Savarese D, Taplin M, Halabi S, Hars V, Kreis W, Vogelzang N . A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol. 1999; 26(5 Suppl 17):39-44. View

Shapiro G, Harper J . Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest. 1999; 104(12):1645-53. PMC: 409893. DOI: 10.1172/JCI9054. View

Seiter K, Feldman E, Halicka H, Deptala A, Traganos F, Burke H . Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia. Br J Haematol. 2000; 108(1):40-7. DOI: 10.1046/j.1365-2141.2000.01804.x. View

Dean P, Jett J . Mathematical analysis of DNA distributions derived from flow microfluorometry. J Cell Biol. 1974; 60(2):523-7. PMC: 2109170. DOI: 10.1083/jcb.60.2.523. View

Sinha A, Blackard C, Seal U . A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer. 1977; 40(6):2836-50. DOI: 10.1002/1097-0142(197712)40:6<2836::aid-cncr2820400614>3.0.co;2-n. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D . New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82(13):1107-12. DOI: 10.1093/jnci/82.13.1107. View

10.

Amos B, Lotan R . Retinoid-sensitive cells and cell lines. Methods Enzymol. 1990; 190:217-25. DOI: 10.1016/0076-6879(90)90026-w. View

11.

Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D . Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991; 83(11):757-66. DOI: 10.1093/jnci/83.11.757. View

12.

Kaufmann S, Desnoyers S, Ottaviano Y, Davidson N, Poirier G . Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993; 53(17):3976-85. View

13.

Formelli F, Cleris L . Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res. 1993; 53(22):5374-6. View

14.

Caliaro M, Marmouget C, Guichard S, MAZARS P, Valette A, Moisand A . Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression. Int J Cancer. 1994; 56(5):743-8. DOI: 10.1002/ijc.2910560522. View

15.

Lotan R . Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res. 1994; 54(7 Suppl):1987s-1990s. View

16.

Haldar S, Negrini M, Monne M, Sabbioni S, Croce C . Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994; 54(8):2095-7. View

17.

Catalona W . Management of cancer of the prostate. N Engl J Med. 1994; 331(15):996-1004. DOI: 10.1056/NEJM199410133311507. View

18.

Lin A, Minden A, Martinetto H, Claret F, Mercurio F, Johnson G . Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science. 1995; 268(5208):286-90. DOI: 10.1126/science.7716521. View

19.

Sacks P, Harris D, Chou T . Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer. 1995; 61(3):409-15. DOI: 10.1002/ijc.2910610322. View

20.

Haldar S, Jena N, Croce C . Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A. 1995; 92(10):4507-11. PMC: 41973. DOI: 10.1073/pnas.92.10.4507. View